About savara inc - SVRA
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
SVRA At a Glance
Savara, Inc.
One Summit Square
Langhorne, Pennsylvania 19047
| Phone | 1-512-614-1848 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -118,837,000.00 | |
| Sector | Health Technology | Employees | 70 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SVRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 6.073 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.207 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.026 |
SVRA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,697,671.429 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SVRA Liquidity
| Current Ratio | 11.846 |
| Quick Ratio | 11.846 |
| Cash Ratio | 11.556 |
SVRA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -50.969 |
| Return on Equity | -63.45 |
| Return on Total Capital | -50.993 |
| Return on Invested Capital | -55.12 |
SVRA Capital Structure
| Total Debt to Total Equity | 14.726 |
| Total Debt to Total Capital | 12.836 |
| Total Debt to Total Assets | 11.803 |
| Long-Term Debt to Equity | 14.723 |
| Long-Term Debt to Total Capital | 12.833 |